EBSCO Logo
Connecting you to content on EBSCOhost
Title

Equisetum arvense: New Evidences Supports Medical use in Daily Clinic.

Authors

Maciel Carneiro, Danilo; Veiga Jardim, Thiago; Luciana Araújo, Ymara Cássia; Carolina Arantes, Ana; Cristina de Sousa, Andrea; Sebba Barroso, Weimar Kunz; Lima Sousa, Ana Luiza; Carlos da Cunha, Luiz; Cardoso Cirilo, Hérica Núbia; Freitas Bara, Maria Teresa; Brandão Veiga Jardim, Paulo César

Abstract

Relevant aspects to the clinical use of Equisetum arvense L. (common horsetail; EA) were reviewed and a search was conducted in the databases PubMed, LILACS, SciELO, Virtual Health Library, Cochrane and Scopus using the keyword "Equisetum arvense" for articles published from 2013 through 2017. So, eighty-eight articles that addressed the pharmacognostic aspects and in vitro and in vivo biological activity, clinical trials with Equisetum arvense (EA) combined with other plants or alone, case reports concerning possible drug interactions and review studies were selected. The most relevant reported pharmacological effects included antioxidant, anticarcinogenic, antimicrobial, vascular and ileum smooth muscle relaxant, analgesic, anti-inflammatory, antinociceptive, cytotoxic, antidiabetic, hepatoprotective, antilithiatic, dermatologic, wound healing, antileishmanial, diuretic, immunizing, platelet aggregation inhibitory, osteoblast response-promoting, remineralizing, anxiolytic, sedative, anticonvulsant and cognitive performance-stimulating activities. Five clinical trials demonstrated the efficacy of phytotherapeutic complexes containing EA, with three for treating benign prostate hyperplasia, one for chronic musculoskeletal pain and one describing the effects of a topical preparation on brittle nail syndrome. Three clinical trials tested EA alone; one analyzed its pharmacokinetics; another addressed the wound-healing effect of 3% EA ointment and a randomized double-blind clinical trial found that the diuretic effect of EA was superior compared to the negative control and equivalent to treatment with hydrochlorothiazide (25 mg/day) without changes in electrolyte excretion. Considering its long history of traditional use in several countries, in vivo and in vitro research and more recent clinical studies, EA meets the requisites for having well-defined medical applications with proven efficacy and acceptable safety.

Subjects

MUSCLE relaxants; VASCULAR smooth muscle; BLOOD platelet aggregation; WOUND healing; CLINICAL trials; DRUG interactions; HEALING; NOCICEPTIVE pain

Publication

Pharmacognosy Reviews, 2019, Vol 13, Issue 26, p50

ISSN

0973-7847

Publication type

Academic Journal

DOI

10.5530/phrev.2019.2.4

EBSCO Connect | Privacy policy | Terms of use | Copyright | Manage my cookies
Journals | Subjects | Sitemap
© 2025 EBSCO Industries, Inc. All rights reserved